"Locked" cancer cells are more sensitive to chemotherapy. Issue 2 (10th June 2019)

• Record Type: Journal Article
• Authors: Lyu, Yaqi; Xiao, Qingqing; Li, Yi; Wu, Yubing; He, Wei; Yin, Lifang
• Other Names: Sullivan Millicent guestEditor.; Sznitman Josué guestEditor.
• Is Part Of: Bioengineering & translational medicine. Volume 4:Issue 2(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-06-10
• Subjects: dual nanomedicines -- extracellular matrix -- matrix metalloproteinase inhibitor -- metastatic cancer -- tumor microenvironment; Bioengineering -- Periodicals; Drug development -- Periodicals; Drugs -- Testing -- Periodicals; 660.6
• DOI: 10.1002/btm2.10130
• Languages: English
• ISSNs: 2380-6761

Abstract

Abstract: The treatment of metastatic cancer is a great challenging issue throughout the world. Conventional chemotherapy can kill the cancer cells and, whereas, would exacerbate the metastasis and induce drug resistance. Here, a new combinatorial treatment strategy of metastatic cancer was probed via subsequentially dosing dual nanomedicines, marimastat‐loaded thermosensitive liposomes (MATT‐LTSLs) and paclitaxel nanocrystals (PTX‐Ns), via intravenous and intratumoral injection. First, the metastasis was blocked and cancer cells were locked in the tumor microenvironment (TME) by delivering the matrix metalloproteinase (MMP) inhibitor, MATT, to the tumor with LTSLs, downregulating the MMPs by threefold and reducing the degradation of the extracellular matrix. And then, the "locked" cancer cells were efficiently killed via intratumoral injection of the other cytotoxic nanomedicine, PTX‐Ns, along with no metastasis and 100% inhibition of tumor growth. This work highlights the importance of the TME's integrity in the chemotherapy duration. We believe this is a generalized strategy for cancer treatment and has potential guidance for the clinical administration.